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84 Poster Session Iengrafted slowly, after Day 42, perhaps related to some underlying
marrow dysfunction caused byMDS. Four patients developed acute
GvHD grades II-IV with a cumulative incidence at 100 Days of
16.7% (95% CI 1.4%-32.0%). Four patients relapsed with a CI of
relapse at 3 years of 15.0% (95% CI 0.0%-31.5%). Cumulative in-
cidence of non-relapse mortality at 1 year was 26.1% (95% CI
7.7%-44.5%). Nine pts died: 4 of infections (2 EBV, 1 adenovirus,
1 toxoplasmosis), 2 of graft failure, 2 of relapse, and 1 of MSOF.
Overall survival probability at 1 and 3 years were 70.4% (95% CI
51.9%-88.8%) and 59.5% (95% CI 38.7%-80.4%) respectively.
Event-free survival (EFS) probabilities at 1 and 3 years were
70.8% (95%CI 52.6%-89.0%) and 59.9% (39.2%-80.7%), respec-
tively. Factors associated with better EFS were age# 10 years (p5
0.03) and weight # 38 kg (p 5 0.02). These results, especially in
younger patients with Monosomy 7 and MDS, are equivalent to
matched allogeneic bone marrow transplant data. UCB should be
actively considered for pediatric MDS patients lacking matched re-
lated or unrelated adult donors.225
THE ADDITION OF ETOPOSIDE TO Bu16/Cy200 IN THE CONDITIONING
OF CHILDREN WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IS ASSOCIATED
WITH IMPROVED SURVIVAL
Ayas, M.1, Al-Mahr, M.1, Al-Jefri, A.1, Al-Seraihi, A.1, Belgaumi, A.1,
Al-Ahmari, A.1, El-Hassan, I.2, El-Solh, H.1. 1King Faisal Specialist
Hospital & Research Center, Riyadh, Saudi Arabia; 2King Faisal Special-
ist Hospital & Research Center, Riyadh, Saudi Arabia.
Relapse remains the major concern for children with AML un-
dergoing SCT, and we have previously shown that intensifying
the conditioning by adding etoposide at 60mg/kg and consequently
reducing the busulfan (Bu) dose to 12mg/kg and the cytoxan (Cy) to
90 mg/kg did not result in any significant improvement of the sur-
vival; we suggested then that the reduction of Bu/Cy doses necessi-
tated by addition of the high dose of etoposide could have affected
the outcome and we hypothesized that adding a lower dose of eto-
poside and keeping the Bu/Cy at the conventional doses may offer
better survival to AML patients undergoing allogeneic SCT. We
present here our results using such a protocol.
Patients andMethods: FromMarch 2003 until December 2006,
33 patients with AML (24 in CR1, 8 in CR 2) underwent allogeneic
SCT and were conditioned with Bu 16 mg/kg po, Cy 200 mg/kg iv
plus etoposide 900 mg/m2 iv, median age was 9.6 years. This cohort
of patients (group B) was compared with 18 AMLpatients (17 in CR
1, 1 in CR 2) who underwent SCT from July 93 thru February 96,
median age at SCT was 7.25 years, patients were conditioned with
only Bu 16 mg/kg po and Cy 200 mg/kg iv (group A).Results:Me-
dian days to ANC$ 500  106/l was 21 days and 15 days in groups
A and B respectively, median days to platelet count$ 20 109/l was
22 days and 26 days in groups A and B respectively (P5 NS). The
incidence of complications was similar, acute GVHD grade 2 or
higher developed in 5% and 9% in groups A and B respectively
(P5 NS), hemorrhagic cystitis developed in 11% and 15% in
groups A and B respectively, no VOD developed in either group.
The 4 year overall survival for groups A and B respectively was
50% and 68.2% (P 5 0.3) and the 4 year event-free survival for
groups A and B respectively was 33% and 68.2% (P5 0.1).Conclu-
sions: The addition of etoposide to Bu16/Cy200 was not associated
with increased toxicity, and although it did not reach statistical sig-
nificance, it does appear to be associated with a better overall and
event-free survival. Larger scale studies are advised to further cor-
roborate our findings.226
SINGLE DAILY DOSE (SDD) BUSULFAN (BU) IN CHILDREN: COMPARI-
SON OF PHARMACOKINETICS (PK) AND ENGRAFTMENT BETWEEN
ACUTE LEUKAEMIA (AL) AND NON MALIGNANT DISEASE (NM)
Shaw, P.J.1,3, Nath, C.E.2, Earl, J.W.2. 1Children’s Hospital at West-
mead, Sydney, NSW, Australia; 2Children’s Hospital at Westmead, Syd-
ney, NSW, Australia; 3University of Sydney, Sydney, NSW, Australia.Methods:We studied BU PK, engraftment and survival in chil-
dren who underwent allogenic BMT for NM (n 5 33) or AL (n 5
41) after BU-based conditioning. The dose of oral BU was 4 mg/kg
(n5 16) or 150 mg/m2 (n 5 32) and intravenous (IV) 3.2 mg/kg (n
5 3), 120 mg/m2 (n5 3) or 130 mg/m2 (n5 20). In 62 cases, blood
was collected after the first dose, BU levels were measured and BU
area-under-the-concentration-versus-time curve (AUC) was deter-
mined using the Kinetica software (Innaphase, USA), then normal-
ized to 130 mg/m2 for IV BU and 150 mg/m2 for oral BU. PK-
guided dose adjustments were made in 7 patients with NM. Total
exposure to BU was determined by dividing first dose AUC by first
dose (mg) and thenmultiplying by the total dose (mg) administered.
Results: In the NM group, 26(79%) are still alive. 5 (of 7) deaths
occurred early (\118 d post BMT) due to transplant-related causes:
VOD (1), VOD and GVHD (2), GVHD (1) and sepsis (1). Full en-
graftment was achieved in all but 5 patients (85%): 2 had stable
mixed chimerism (MC) .95% donor, 3 had inadequate engraft-
ment; 4 of these were part of a group of 12 who hadT cell depletion.
Total Bu exposure ranged from 57 to 146 mg/L.h (median 90 mg/
L.h). In the AL group, 29 (71%) are still alive, with 4 early trans-
plant-related deaths from GVHD (2), relapse (1) and sepsis (1).
Full engraftment was achieved in all but 3 patients (93%): 2 children
had MC and one of these subsequently lost the graft, another was
fully donor but died prior to obtaining full haematological recovery.
Total Bu exposure ranged from 40 to 345 mg/L.h (median 99 mg/
L.h). Results of the normalised AUC (nAUC) in mg/L.h are shown
in the table. nAUC was significantly higher in the oral BU group (n
5 36) than in the IV BU group (n5 26): 276 6mg/L.h versus 236
8 mg/L.h, p\0.01.Conclusions: Single daily dose BU is generally
safe and effective for use in children with AL andNM. A dose of 130
mg/m2 IV gives less exposure than 150mg/m2 oral.Wide variability
in BU pharmacokinetics indicates a need for measurement and per-
haps targeting in some patients, especially those with immune defi-
ciencies or those more likely to reject.normalised AUC (nAUC) mg/L.h
Diagnosis: Genetic SCID non-SCID ALIV Bu
nAUC (range) 20–44 14–50 18–31 14–30
median 23 16 21 18
fold variation 2.2 3.6 1.9 2.2
n 6 3 7 10Oral Bu
nAUC (range) 15–38 18–25 27–36 15–43
median 25 25 30 28
fold variation 2.5 1.4 1.3 2.9
n 9 3 4 20227
FUNGAL INFECTIONS: A SURVEY OF PEDIATRIC SURVEY OF PEDIATRIC
BLOOD & MARROW TRANSPLANT CONSORTIUM INSTITUTIONS
Fisher, V.L.1, Olson, E.A.2. 1Rainbow Babies & Children’s Hospital,
Cleveland, OH; 2Children’s Healthcare of Atlanta, Atlanta, GA.
This survey was designed to identify the fungal infectionmanage-
ment used for the pediatric BMT patient and to develop a standard
of care for fungal infection management by institutions within the
Pediatric Blood & Marrow Transplant Consortium (PBMTC).
Twenty five percent of the surveys were returned. 100%of the in-
stitutions performed allogeneic and autologous transplants. Non-
myeloablative transplants were performed by 89% of the institu-
tions.
All institutions used some type of fungal prophylaxis during
transplant, 77% used fungal prophylaxis on all their transplant pa-
tients. 50% of the centers differed on the prophylaxis used in the
BMT sub-groups, with 85% of the centers using Fluconazole,
and 15% of the institutions using no prophylaxis in autologous pa-
tients. 100% of centers administered prophylaxis to the allogeneic
transplant group. The break down of agents utilized in the allo-graft
group was Fluconazole (47%), Voriconazole (23%) and low dose
